Loading
A single dose of carboplatin was as effective as radiotherapy in preventing relapse of stage I seminoma after orchidectomy, with less time off work and fewer second testicular cancers, so it replaced radiotherapy for men who choose adjuvant treatment.
Phase 3 non-inferiority trial of 1,477 men with stage I seminoma randomised to adjuvant radiotherapy or one cycle of carboplatin (AUC 7).
Three-year relapse-free rates were 94.8 percent with carboplatin and 95.9 percent with radiotherapy (non-inferior), with fewer contralateral germ cell tumours after carboplatin and less acute toxicity; longer follow-up confirmed equivalence.
Single-dose carboplatin is the adjuvant option for stage I seminoma where surveillance is not chosen; radiotherapy is now rarely used because of second cancer risk.
Shares The Lancet, Carboplatin.
Shares The Lancet, Carboplatin.
Shares Seminoma, Carboplatin.
Shares The Lancet, Carboplatin.
Shares The Lancet, Carboplatin.